The capital infusion is earmarked to advance the company's CXCL10 monoclonal antibody program through the end of fiscal 2026. The private placement included 834 Series B-1 convertible preferred ...

Cleo Diagnostics (ASX:COV) has received an A$845,172.16 cash refund from the Australian Government under the FY24 Research ...